Ditchcarbon
  • Contact
  1. Organizations
  2. Camurus
Public Profile
Pharmaceutical Preparation Manufacturing
SE
updated a month ago

Camurus

Company website

Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.

DitchCarbon Score

How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

34

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Camurus's score of 34 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

56%

Let us know if this data was useful to you

Camurus's reported carbon emissions

In 2023, Camurus, headquartered in Sweden (SE), reported total carbon emissions of approximately 5,618,000 kg CO2e. This figure includes Scope 1 emissions of about 1,589,000 kg CO2e, Scope 2 emissions of approximately 1,748,000 kg CO2e, and Scope 3 emissions totalling around 3,856,000 kg CO2e. Notably, the company has set ambitious greenhouse gas reduction targets, aiming for a 55% reduction by 2030 from a 2019 baseline across all scopes. Additionally, Camurus is committed to achieving carbon neutrality by 2040, specifically targeting a 35% reduction in Scope 1 emissions by 2025. These initiatives reflect the company's dedication to addressing climate change and reducing its environmental impact.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
162,400
0,000,000
Scope 2
8,990
00,000
Scope 3
60,300
0,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Camurus's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Camurus is in SE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Camurus is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Horizon Therapeutics Public Limited Company

IE
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Swedish Orphan Biovitrum

SE
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Td Medtekhnologii, Ooo

RU
•
Food products nec
Updated 9 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251028.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy